Overview

Choosing a gastric cancer regimen increasingly means combining a targeted agent with cytotoxic chemotherapy, but the combination must be justified by the tumor profile. The 90-gene gastric test reports not only druggable alterations but also chemotherapy-sensitivity markers and mismatch-repair status, giving the prescriber a single document on which to base a rational combination rather than a list of isolated positives.

How It Works

The assay sequences ninety genes covering receptor tyrosine kinases, cell-cycle regulators, and DNA-repair pathways, then cross-references each finding with published sensitivity evidence. HER2 and MET amplification, Claudin18.2 relevance, and MSI-H status are flagged together with markers that predict chemo response, such as alterations in thymidylate synthase pathways. The report ranks findings so the strongest targets rise to the top of the combination plan, and weaker signals are presented as context rather than as primary drivers.

Indications

This profile suits advanced gastric cancer where a sequenced combination of targeted and cytotoxic drugs is planned. It helps avoid adding an expensive agent that the tumor lacks the target for, and it highlights cases where microsatellite instability favors an immune-based backbone over a conventional doublet chemotherapy. The integrated view also supports discussions about sequencing when resistance eventually emerges.

Specimen & Turnaround

The lab accepts an FFPE block or a set of unstained slides, with nucleic acid quality checked before the library build begins. Reporting returns in roughly seven to ten business days, including an interpretive summary written for the treating oncologist and a table of therapy-linked alterations.

Storage & Logistics

Reagent lots are temperature-qualified for export, and the panel is supplied with batch certificates for auditing. Distributors can schedule standing weekly pickups to keep hospital turnaround predictable and to reduce cold-chain handling steps. The interpretive summary is written in plain language so non-specialist procurement and nursing staff can also follow the rationale behind each recommended combination. Because the report groups findings by therapy class, the multidisciplinary board can reach a decision in a single meeting rather than waiting for several separate consultations.

FAQ

Q: How does the 90-gene test support combination therapy? A: It reports targeted alterations, chemo-sensitivity markers and MSI status together, so a rational targeted-plus-chemo plan can be built from one profile.

Q: Will it tell me which chemotherapy to keep? A: It adds sensitivity markers that inform chemo choice, but final regimen selection remains a clinical decision with the care team.

Q: Is MSI status included in the same report? A: Yes, mismatch-repair and microsatellite findings are reported alongside the gene list so immune eligibility is clear.